An Assessment of the Publicly Disseminated Evidence of Safety Used in Decisions to Withdraw Medicinal Products from the UK and US Markets

Author： Clarke Andrea  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.29, Iss.2, 2006-01, pp. : 175-181

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Safety of Herbal Medicinal Products Derived from Echinacea Species: A Systematic Review

By Huntley Alyson L.   Joanna Thompson Coon   Ernst Edzard  

Drug Safety, Vol. 28, Iss. 5, 2005-01 ,pp. : 387-400

Adis International

Access to resources Recommend Favorite

Growth in the US, UK and Swedish pharma markets in 2002

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 401, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

The Role of Health-Related Quality of Life Data in the Drug Approval Processes in the US and Europe: A Review of Guidance Documents and Authorizations of Medicinal Products from 2006 to 2010

By Marquis Patrick  

Pharmaceutical Medicine, Vol. 25, Iss. 3, 2011-06 ,pp. : 147-160

Adis International

Access to resources Recommend Favorite

The Development of Herbal Medicinal Products: Quality, Safety and Efficacy as Key Factors

By Cañigueral Salvador  

Pharmaceutical Medicine, Vol. 22, Iss. 2, 2008-01 ,pp. : 107-118

Adis International

Access to resources Recommend Favorite

Leo Pharma to withdraw drugs from Greece

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 605, 2010-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite